{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-045343","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.179015+00:00","generated_at":"2026-05-30T04:38:30.334174+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunocore Q3 2024: KIMMTRAK revenue $80.2M (+28% YoY); EPS $0.17; CFO to depart","bullets":["KIMMTRAK net revenue $80.2M in Q3 2024, up 28% vs $62.6M in Q3 2023; US $57.3M, Europe $21.0M.","GAAP EPS $0.17 (diluted), net income $8.7M vs $0.9M in Q3 2023; cash $901.3M at Sept 30, 2024.","CFO Brian Di Donato to leave end of 2024; search for replacement in progress.","Brenetafusp (PRAME-A02) Phase 1 data at ESMO; NSCLC signal-detection shift delays initial data release.","Plans to repay $50M loan by end of 2024; pay ~$40M in sales-related rebate accruals in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-045343","json":"https://secwatch.observer/filing/0001140361-24-045343.json","markdown":"https://secwatch.observer/filing/0001140361-24-045343.md","text":"https://secwatch.observer/filing/0001140361-24-045343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124045343/0001140361-24-045343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124045343/ef20038108_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:38:30.334174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}